Irena Royzman

Eugene Gelernter

Irena Royzman is a Partner with Kramer Levin, where she represents pharmaceutical, biotech and medical device companies in patent litigation, advising both plaintiffs and defendants in every stage of the litigation process from pre-suit investigation through trials and appeals. She litigates a wide range of subject matters including small molecule drugs, antibodies, manufacturing processes, point-of-care diagnostics, gene-editing technology, gene therapies, and drug-eluting coatings. She has a particular depth of experience in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA). In addition, she represents clients in inter partes reviews and high-stakes license disputes. Irena also provides strategic counseling in the area of biologics and pharmaceuticals and advises clients on contractual and licensing issues.

To read more about Ms. Royzman or to contact her, please visit her firm profile page.


Posts by Irena Royzman


The AIA does not restrict judicial review of a final written decision

The AIA and its legislative history do not provide clear and convincing evidence that Congress intended ultra vires agency action by the PTO in holding claims unpatentable …

Will SCOTUS Provide Guidance on Judicial Review and Claim Construction for IPR Proceedings?

The NYIPLA asks the Court to grant the petition in order to make clear that judicial review is available when the PTO institutes an IPR proceeding and …

The Mayo Framework Does Not Moot Preemption

While Mayo and Alice presented a two-part "framework" to address when a particular claimed invention preempts a "fundamental principle," neither case purported to have that framework replace …
By Irena Royzman & Alicia Russo
4 years ago 3